BI 2536

BI 2536 Basic information
Product Name:BI 2536
Synonyms:BI-2536, BoehringerPLK-1 inhibitor;4-[[(7R)-8-Cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)benzamide;BI 2536;Benzamide, 4-[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-;Boehringer PLK-1 inhibitor;BI-2536(R-);BI2536/BI-2536;(R)-4-((8-cyclopentyl-7-ethyl-5-Methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)aMino)-3-Methoxy-N-(1-Methylpiperidin-4-yl)benzaMide
CAS:755038-02-9
MF:C28H39N7O3
MW:521.65
EINECS:1308068-626-2
Product Categories:Inhibitors;API
Mol File:755038-02-9.mol
BI 2536 Structure
BI 2536 Chemical Properties
density 1.28
storage temp. Keep in dark place,Sealed in dry,Store in freezer, under -20°C
solubility Soluble in DMSO (up to 20 mg/ml) or in Ethanol (up to 25 mg/ml)
form Yellow powder.
pka14.09±0.20(Predicted)
color Off-white
Stability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.
Safety Information
MSDS Information
BI 2536 Usage And Synthesis
DescriptionBI 2536 (755038-02-9) was originally reported as a potent (IC50’s Plk1 = 0.83nM, Plk2 = 3.5nM and Plk3 = 9.0nM)1?and selective2?Polo-like kinase inhibitor?that caused mitotic arrest and apoptosis induction in various human cancer cell lines.1?It was later found to be a potent inhibitor (IC50?= 100nM) of BET family member BRD4 and able to potently suppress c-Myc expression in MM.1S multiple myeloma cells.3?BI 2536 destabilizes N-Myc by inhibiting the deactivation of the ubiquitin E3 ligase Fbw7 by Plk1.4
UsesBI 2536 is a PLK1 inhibitor, inducing apoptosis together with micro-tubule-destabilizing drugs in preclinical rhabdomyosarcoma models. Anti-cancer and potent PLK1 inhibitor.
targetPlk1
References1) Steegmaier?et al.?(2007),?BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo; Curr. Biol.,?17?316 2) Davis?et al.?(2011),?Comprehensive analysis of kinase inhibitor selectivity; Nat. Biotechnol.,?29?1046 3) Ciceri?et al.?(2014),?Dual kinase-bromodomain inhibitors for rationally designed polypharmacology; Nat. Chem. Biol.,?10?305 4) Xiao?et al.?(2016),?Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival; Mol. Cell,?64?493
BI 2536 Preparation Products And Raw materials
Olaparib Afatinib Volasertib (BI 6727) D-ERYTHRO-SPHINGOSINE PD 0332991 HCl Glucagon Receptor Antagonist I Neratinib N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide hydrochloride Tubastatin A hydrochloride Alpelisib (BYL719) Fluoxetine hydrochloride CX-4945 Alisertib (MLN8237) N-[3-[(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]-2,4-difluorophenyl]-1-propanesulfonamide BML-275 Selumetinib Bortezomib BI 2536

Email:[email protected] [email protected]
Copyright © 2024 Mywellwork.com All rights reserved.